Novo Nordisk(NONOF)

BAGSVAERD DENMARK, DenmarkPharmaceutical1 H-1B visas (FY2023)

Focus: Novo Nordisk is a global pharmaceutical leader headquartered in Denmark, founded in 1923, with deep expertise in diabetes, obesity, and hemophilia treatments. The company commands massive market share through blockbuster GLP-1 therapies, particularly Ozempic, which alone represents 61% of revenues.

Cell Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Open Jobs

15+15 this month

Growing — net +15 jobs in 30d

22 jobs added vs 7 removed. Steady team buildout.

2 recent layoff filings (12 mo) — 1,622 affected

9/1/2025 — Plainsboro, NJ · 811 affected · Layoff
9/1/2025 — Plainsboro, NJ · 811 affected · Layoff

Source: state DOL filings via Big Local News

Should You Work at Novo Nordisk?

AI assessment

Strong entry point for commercial or regulatory careers banking on GLP-1 dominance, but pipeline thinness and recent headcount cuts signal cyclical restructuring risk—best for risk-tolerant professionals in the next 2–3 years.

Why Work Here

Lead the global obesity epidemic response: Ozempic ($9.2B Part D spend) and Rybelsus ($1.7B) position you at the center of a decade-long market expansion with patent protection through 2038–2039.

Data completeness

4/9 — Basic

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

Protected

No near-term cliffs

Hiring

Slowing

Jobs decreasing

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

OZEMPIC

GLP-1 Receptor Agonist

$9.2B Part D

Peak

Help build intelligence for Novo Nordisk

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Stable, cash-generative platform: A century-old public company with proven commercial infrastructure and recurring revenue from insulin analogs (NovoLog, Levemir combined ~$3B) provides job security.

Emerging pipeline breadth: 30 active programs spanning GLP-1 combinations (Cagrilintide Phase 3), heart failure (CDR132L Phase 2), and rare bleeding disorders offer career growth beyond diabetes.

Watch Out For

Massive patent cliff risk: Insulin analogs (NovoLog, Levemir) face LOE imminently with no disclosed dates; loss of exclusivity will erode ~$3B in revenue and likely trigger restructuring.
Recent large layoff signal: 811 employees cut at Plainsboro, NJ (Sept 2025) suggests ongoing portfolio consolidation and job instability despite headline revenue strength; Ozempic shortage indicates supply-chain stress.

Generated by Claude from Novo Nordisk's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Blockbuster anchor driving 61% of company revenue; patent protection extends to 2038, but high-profile shortages due to demand surge create execution risk.

NOVOLOG FLEXPEN

Insulin Analog

$1.9B Part D

LOE Approaching

Core legacy franchise approaching loss of exclusivity with no disclosed expiration date; significant revenue cliff risk.

RYBELSUS

GLP-1 Receptor Agonist

$1.7B Part D

Peak12.6yr

Oral formulation of semaglutide extending GLP-1 franchise durability; patent cliff deferred to 2039.

LEVEMIR FLEXPEN

Insulin Analog

$1.0B Part D

LOE Approaching

Long-acting insulin analog facing imminent generic competition; no LOE date disclosed heightens uncertainty.

NOVOLOG

Insulin Analog

$517M Part D

LOE Approaching

Rapid-acting insulin approaching LOE; market erosion likely within 3–5 years.

LEVEMIR

Insulin Analog

$287M Part D

LOE Approaching

Basal insulin with approaching LOE and no disclosed expiration; contributing to $1.5B+ insulin detemir franchise cliff.

LEVEMIR

Glycemic control in adults

$287M Part D

LOE Approaching

Duplicate entry for insulin detemir; underscores market fragmentation and LOE proximity.

LEVEMIR FLEXTOUCH

Insulin Analog

$184M Part D

LOE Approaching

Device-integrated insulin detemir formulation approaching LOE; contributes to combined detemir cliff risk.

FIASP FLEXTOUCH

Insulin Analog

$106M Part D

Peak

Faster-acting insulin aspart with device convenience; smaller franchise with stable sales but limited growth.

NOVOLIN N

Insulin

$53M Part D

LOE Approaching

Legacy human insulin product with minimal revenue and approaching LOE; immaterial to portfolio.

Pipeline & Clinical Trials

Combining Registry Data in Haemophilia: TARGET H

Haemophilia

N/A

Clinical Trials (1)

NCT03264014Combining Registry Data in Haemophilia: TARGET H

N/A

activated recombinant human factor VII

Congenital Bleeding Disorder

N/A

Clinical Trials (1)

NCT01312636Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII Deficiency

N/A

Video instruction

Musculoskeletal Disorders

N/A

Clinical Trials (1)

NCT01543893Effect of Personal Versus Video Instruction in Elastic Resistance Exercise on Technical Execution (IRMA05)

N/A

Cardiac Mitochondrial Function After Heart Transplantation

Cardiac Allograft Vasculopathy

N/A

Clinical Trials (1)

NCT04105803Cardiac Mitochondrial Function After Heart Transplantation

N/A

gastric bypass surgery and testing

Gastric Bypass

N/A

Clinical Trials (1)

NCT00915980Meal Stimulating After Roux-en Y Gastric Bypass

N/A

Vira mobile app intervention

Mental Health Disorder

N/A

Clinical Trials (1)

NCT05638516Improving Mental Health in Youth and Lowering Risk for Obesity Through a Digital Preventative Product

N/A

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

Hematologic Disorder

N/A

Needs assesment tool integrated in nursing consultation.

Head and Neck Neoplasms

N/A

Clinical Trials (1)

NCT03443258Needs Assessment Tool Integrated in Clinical Practice of Head and Neck Cancer Rehabilitation

N/A

transient elastography

Liver Diseases, Alcoholic

N/A

No treatment given

Haemostasis

N/A

Clinical Trials (1)

NCT02568202Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)

N/A

The Nordic Rectal Prolapse Study

Rectal Prolapse

N/A

Clinical Trials (1)

NCT05569980The Nordic Rectal Prolapse Study

N/A

activated recombinant human factor VII

Acquired Bleeding Disorder

N/A

Clinical Trials (1)

NCT00124293Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury

N/A

No treatment given

Haemophilia

N/A

Clinical Trials (1)

NCT07163260Defeat Rare Disease in Asia and Pacific (APAC) DRDA - Haemophilia

N/A

activated recombinant human factor VII

Congenital Bleeding Disorder

N/A

Clinical Trials (1)

NCT01476423Observational Registry of the Treatment of Glanzmann's Thrombasthenia

N/A

Eptacog alfa

Post Partum Hemorrhage

N/A

Clinical Trials (1)

NCT04723979NovoSeven® in Severe Postpartum Haemorrhage - Experiences From UK, DK, FR, NL

N/A

Biological mesh

Abdominal Donor-site

N/A

Clinical Trials (1)

NCT02076724Reinforcement of the Abdominal Wall After Breast Reconstruction With the Pedicled TRAM-flap

N/A

Eptacog alfa

Severe Postpartum Haemorrhage

N/A

Clinical Trials (1)

NCT04444856Clinical Outcomes of NovoSeven® Treatment in Severe Postpartum Haemorrhage - a Study at the University Hospital of Bern

N/A

No treatment given

Congenital Bleeding Disorder

N/A

Clinical Trials (1)

NCT01322620Survey Evaluating the Psychosocial Effects of Living With Haemophilia

N/A

Live music in the intensive care unit

Stress

N/A

Clinical Trials (1)

NCT06442644Live Music in the Intensive Care Unit

N/A

Infusion of GIP[1-42], GIP[1-30] or placebo

Type1diabetes

N/A

Clinical Trials (1)

NCT06137586The Effect of Glucose-dependent Insulinotropic Polypeptide on the Alpha Cell Response to Hypoglycaemia in Patients with Type 1 Diabetes

N/A

HM-PRO

Hematologic Malignancy

N/A

Clinical Trials (1)

NCT04757545Symptom Identification and Management in Patients With Hematological Malignancy During Follow-up Care

N/A

Complex lifestyle intervention

Lifestyle, Healthy

N/A

Clinical Trials (1)

NCT06122441RE-inventing Strategies for Healthy Ageing; Recommendations and Tools

N/A

Treatment Decision-making in Patients With Recurrent High-grade Glioma

Malignant Glioma

N/A

Clinical Trials (1)

NCT04013828Treatment Decision-making in Patients With Recurrent High-grade Glioma

N/A

No treatment given

Congenital Bleeding Disorder

N/A

Clinical Trials (1)

NCT02241694To Quantify the Range of Main Psychosocial Factors Affecting Patients and Caregivers in Their Daily Lives

N/A

Preventive treatment with IV-hydration

Contrast-induced Nephropathy

N/A

Clinical Trials (1)

NCT05283512Intravenous vs. Oral Hydration to Reduce the Risk of Post-Contrast Acute Kidney Injury After Intravenous Contrast-Enhanced Computed Tomography in Patients With Severe Chronic Kidney Disease

N/A

recombinant factor XIII

Congenital Bleeding Disorder

N/A

Clinical Trials (1)

NCT02670213A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan

N/A

Physical activity

Intellectual Disability

N/A

Clinical Trials (1)

NCT05336487Physical Activity, Sports and Health in Adults With Intellectual Disabilities

N/A

eptacog alfa

Congenital Bleeding Disorder

N/A

Clinical Trials (1)

NCT01579968Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing Surgery

N/A

Single anastomosis duodeno-ileal bypass

Enteroendocrine Physiological Changes in Superobese Patients Submitted to Two Different Bariatric Procedures

N/A

Clinical Trials (1)

NCT04712409Surgical Innovation for Diabetes Treatment 2

N/A

No treatment given

Growth Disorder

N/A

Clinical Trials (1)

NCT02580032Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)

N/A

NordiFlex PenMate™

Growth Hormone Disorder

N/A

Clinical Trials (1)

NCT01500486Observational Study of Norditropin NordiFlex® With NordiFlex PenMate™

N/A

VIA Family 2.0

Child

N/A

Kidney Biopsy

Chronic Kidney Diseases

N/A

Clinical Trials (1)

NCT04916132Diabetic Nephropathy in People With Diabetes. Prevalence and Predictive Factors

N/A

catridecacog

Congenital Bleeding Disorder

N/A

Clinical Trials (1)

NCT01862367Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study

N/A

Examination of Biopsies From Healthy Knee Joints

Abnormality in Synovial Tissue

N/A

Clinical Trials (1)

NCT02458170Examination of Biopsies From Healthy Knee Joints

N/A

Multi-level, Multi-component Intervention Package

Quality of Life (QOL)

N/A

Clinical Trials (1)

NCT07061665Cities for Better Health Childhood Obesity Prevention Initiative in JAPAN

N/A

Cross-over study

T2D

N/A

Clinical Trials (1)

NCT04011904The Role of Traditional or Western Diet in the TBC1D4 Gene on Glucose Homeostasis in Greenland Inuits

N/A

Meal Test

Bone Remodeling

N/A

Clinical Trials (1)

NCT02518737Examination of the Postprandial Bone Remodeling in Persons With Reduced GIP-Receptor Activity

N/A

no treatment

Quality of Life

N/A

Clinical Trials (1)

NCT02965144Long Term Survivors of High-grade Glioma and Their Caregivers

N/A

eptacog alfa

Congenital Bleeding Disorder

N/A

Clinical Trials (1)

NCT01579955Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical Practice

N/A

No treatment given

Congenital Bleeding Disorder

N/A

Clinical Trials (1)

NCT01988532Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia

N/A

Fibroblast growth factor 21 infusion

Fibroblast Growth Factor 21

N/A

Clinical Trials (1)

NCT04232033The Physiological Effects of FGF21 on Alcohol Preference and Glucose Metabolism

N/A

activated recombinant human factor VII

Acquired Bleeding Disorder

N/A

Clinical Trials (1)

NCT01285089Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia

N/A

There is no intervention

Diabetic Nephropathies

N/A

Sodium-glucose cotransporter 2 inhibitors

Diabetic Nephropathies

N/A

activated recombinant human factor VII

Congenital Bleeding Disorder

N/A

Clinical Trials (1)

NCT01220141Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B

N/A

No Intervention

Pregnancy

N/A

Clinical Trials (2)

NCT07560059Acute Metabolic Outcomes in Diabetic Patients Hospitalized for COVID-19 (DMD-COV)

N/A

NCT05872022A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy

N/A

No treatment given

Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) & Steatohepatitis (MASH)

N/A

Clinical Trials (1)

NCT06741111A Real-world Assessment in Implementation of the MASH Patient Care Pathway in Chinese Population Using the Meinian Health Check-up Database

N/A

eptacog alfa

Congenital Bleeding Disorder

N/A

Clinical Trials (1)

NCT01830712A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors

N/A

observational study

Hemorrhage

N/A

Clinical Trials (1)

NCT01532661National Registry of rFVIIa (Novoseven) in Haemorrhagic Traumatology

N/A

Interview Prep Quick Facts

Founded: 1923

Portfolio: 47 approved products, 146 clinical trials

Top TAs: Metabolic Diseases, Endocrinology, Nephrology

H-1B (2023): 1 approval

Open Roles: 15 active jobs

Portfolio Health

Launch3 (6%)

Growth2 (4%)

Peak15 (32%)

LOE Approaching26 (55%)

Post-LOE1 (2%)

47 total products

Therapeutic Area Focus

Metabolic Diseases

34 marketed1186 pipeline

Endocrinology

3 marketed55 pipeline

Nephrology

6 marketed41 pipeline

Cardiovascular

4 marketed40 pipeline

Hiring Trend

Slowing Down

Open Roles

Added

-7

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (2)

2025-09-01

811 employees affected— Plainsboro, NJ

2025-09-01

811 employees affected— Plainsboro, NJ

Source: state DOL filings, aggregated via Big Local News

1 active drug shortage

mAbINJECTION · SOLUTION

Concizumab-mtci is a monoclonal antibody antagonist of endogenous Tissue Factor Pathway Inhibitor (TFPI). Through the inhibition of TFPI, concizumab-mtci acts to enhance FXa production during the initiation phase of coagulation which leads to improved thrombin generation and clot formation with the goal of achieving hemostasis in patients with Hemophilia A or B regardless of their inhibitor status. The effect of concizumab-mtci is not influenced by the presence of inhibitory antibodies to FVIII or FIX. There is no structural relationship or sequence homology between concizumab-mtci and FVIII or FIX and, as such, treatment with concizumab-mtci does not induce or enhance the development of direct inhibitors to FVIII or FIX.

AWIQLI FLEXTOUCH

insulin icodec-abae

Launch

SOLUTION · INJECTION

2026

Gastroenterology

4 marketed39 pipeline

Immunology

3 marketed25 pipeline

Oncology

3 marketed24 pipeline

Infectious Diseases

5 marketed21 pipeline

811 employees laid off at Plainsboro, NJ facility in September 2025, coinciding with Ozempic supply shortages and likely triggered by margin pressure from manufacturing bottlenecks and upcoming insulin patent erosion.

Dual layoff filings at same location suggest duplicate reporting or phased reduction; combined with Ozempic shortage and undisclosed insulin LOE dates, workforce stability is compromised—exercise caution on multi-year tenure assumptions.

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Novo Nordisk(NONOF)

Should You Work at Novo Nordisk?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (18)

Key Products by Revenue

Other Products (7)

Pipeline & Clinical Trials

Open Jobs (15)

Automation & Tooling Manager- Customer Operations

Recruiter

Senior IT Support Engineer

Payments Program Manager

Senior Designer

Product & Regulatory Counsel

Senior Manager of Fraud Strategy and Analytics

BSA Manager

Senior Fraud Analyst

Lead Devops Engineer

Senior Analytics - Strategy and Analytics

Principal Engineer

Technical Lead

Senior Community Manager- Marketing

Account Servicing Specialist (Collections and Recovery)

Hiring Trend

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (2)